NANOBIOTIX Reports New Data For Potential First-In-Class Radioenhancer NBTXR3 In Combination With Anti-PD-1 Showing Local Or Distant Tumor Regression In 76.9% Of Evaluable Patients Regardless Of Prior Anti-PD-1 Exposure
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients…